These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 36600260)
1. Response to back-to-back outbreaks of circulating vaccine-derived poliovirus type 2 in two nomadic pastoralist settlements in Oti Region, Ghana-2019. Ameme DK; Yeboah YO; Odoom JK; Djokoto SK; Akyereko E; Mamudu A; Diwura M; Opare W; Avevor P; Diamenu S; Ohene SA; Kenu E; Asiedu-Bekoe F Arch Public Health; 2023 Jan; 81(1):1. PubMed ID: 36600260 [TBL] [Abstract][Full Text] [Related]
2. Risk factors for the spread of vaccine-derived type 2 polioviruses after global withdrawal of trivalent oral poliovirus vaccine and the effects of outbreak responses with monovalent vaccine: a retrospective analysis of surveillance data for 51 countries in Africa. Cooper LV; Bandyopadhyay AS; Gumede N; Mach O; Mkanda P; Ndoutabé M; Okiror SO; Ramirez-Gonzalez A; Touray K; Wanyoike S; Grassly NC; Blake IM Lancet Infect Dis; 2022 Feb; 22(2):284-294. PubMed ID: 34648733 [TBL] [Abstract][Full Text] [Related]
3. Strategic Response to an Outbreak of Circulating Vaccine-Derived Poliovirus Type 2 - Syria, 2017-2018. Mbaeyi C; Wadood ZM; Moran T; ; Ather F; Stehling-Ariza T; Nikulin J; Al Safadi M; Iber J; Zomahoun L; Abourshaid N; Pang H; Collins N; Asghar H; Butt OUI; Burns CC; Ehrhardt D; Sharaf M MMWR Morb Mortal Wkly Rep; 2018 Jun; 67(24):690-694. PubMed ID: 29927908 [TBL] [Abstract][Full Text] [Related]
4. Effectiveness of poliovirus vaccines against circulating vaccine-derived type 2 poliomyelitis in Nigeria between 2017 and 2022: a case-control study. Cooper LV; Erbeto TB; Danzomo AA; Abdullahi HW; Boateng K; Adamu US; Shuaib F; Modjirom N; Gray EJ; Bandyopadhyay AS; Zipursky S; Okiror SO; Grassly NC; Blake IM Lancet Infect Dis; 2024 Apr; 24(4):427-436. PubMed ID: 38246190 [TBL] [Abstract][Full Text] [Related]
5. Analysis of a Sabin-Strain Inactivated Poliovirus Vaccine Response to a Circulating Type 2 Vaccine-Derived Poliovirus Event in Sichuan Province, China 2019-2021. Yang H; Qi Q; Zhang Y; Wen N; Cao L; Liu Y; Fan C; Yan D; Zhu X; Hao L; Zhu S; Ma Q; Liu J; Ma C; Nan L; Chen Y; Ma X; Chen N; Deng K; Shao G; Ding X; An Z; Rodewald LE; Li X; Wang D; Zhu H; Wang H; Feng Z; Xu W; Zhou J; Yin Z; JAMA Netw Open; 2023 Jan; 6(1):e2249710. PubMed ID: 36602797 [TBL] [Abstract][Full Text] [Related]
6. Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine use. Duintjer Tebbens RJ; Hampton LM; Thompson KM BMC Infect Dis; 2016 Jun; 16():237. PubMed ID: 27246198 [TBL] [Abstract][Full Text] [Related]
7. Modeling the spread of circulating vaccine-derived poliovirus type 2 outbreaks and interventions: A case study of Nigeria. Sun Y; Keskinocak P; Steimle LN; Kovacs SD; Wassilak SG Vaccine X; 2024 Jun; 18():100476. PubMed ID: 38617838 [TBL] [Abstract][Full Text] [Related]
8. Detection of vaccine-derived poliovirus circulation by environmental surveillance in the absence of clinical cases. Odoom JK; Obodai E; Boateng G; Diamenu S; Attiku K; Avevor P; Duker E; Boahene B; Eshun M; Gberbie E; Opare JKL Hum Vaccin Immunother; 2021 Jul; 17(7):2117-2124. PubMed ID: 33517832 [TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials. De Coster I; Leroux-Roels I; Bandyopadhyay AS; Gast C; Withanage K; Steenackers K; De Smedt P; Aerssens A; Leroux-Roels G; Oberste MS; Konopka-Anstadt JL; Weldon WC; Fix A; Konz J; Wahid R; Modlin J; Clemens R; Costa Clemens SA; Bachtiar NS; Van Damme P Lancet; 2021 Jan; 397(10268):39-50. PubMed ID: 33308429 [TBL] [Abstract][Full Text] [Related]
14. Sequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis. Ciapponi A; Bardach A; Rey Ares L; Glujovsky D; Cafferata ML; Cesaroni S; Bhatti A Cochrane Database Syst Rev; 2019 Dec; 12(12):CD011260. PubMed ID: 31801180 [TBL] [Abstract][Full Text] [Related]
15. Introduction of Inactivated Poliovirus Vaccine and Switch from Trivalent to Bivalent Oral Poliovirus Vaccine - Worldwide, 2013-2016. Immunization Systems Management Group of the Global Polio Eradication Initiative MMWR Morb Mortal Wkly Rep; 2015 Jul; 64(25):699-702. PubMed ID: 26135591 [TBL] [Abstract][Full Text] [Related]
16. Estimation of oral poliovirus vaccine effectiveness in Afghanistan, 2010-2020. Chard AN; Martinez M; Matanock A; Kassem AM Vaccine; 2021 Oct; 39(42):6250-6255. PubMed ID: 34538696 [TBL] [Abstract][Full Text] [Related]
17. Introduction of inactivated poliovirus vaccine leading into the polio eradication endgame strategic plan; Hangzhou, China, 2010-2014. Liu Y; Wang J; Liu S; Du J; Wang L; Gu W; Xu Y; Zuo S; Xu E; An Z Vaccine; 2017 Mar; 35(9):1281-1286. PubMed ID: 28161421 [TBL] [Abstract][Full Text] [Related]
18. [Discovery of Foci of Type-2 Poliovirus Derived from Oral Polio Vaccine in Central African Republic in 2019]. Kalthan E; Gouandjika-Vasilache I; Mbailao R; Doté JW; Kossone MN; Gbangai M Med Trop Sante Int; 2021 Jun; 1(2):. PubMed ID: 35586583 [TBL] [Abstract][Full Text] [Related]